Geoffrey Prévot
Scientist, Early Formulation & Drug Profiling Servier
Dr. Geoffrey Prévot holds a Ph.D. in nanomedicine from the University of Bordeaux, France, where his research focused on the development of advanced drug delivery systems. He subsequently completed a postdoctoral fellowship at the Icahn School of Medicine at Mount Sinai (New York, USA), where he worked on lipid nanoparticles and bioinspired nanocarriers.
Dr. Prévot is currently a scientist on the Early Formulation and Drug Profiling team at the Servier Research Institute in Saclay, France. His work supports Servier’s mission as an independent, research-driven pharmaceutical company committed to therapeutic innovation to meet patient needs particularly in the fields of oncology, neurology, and cardiometabolism.
With a strong interdisciplinary background in nanotechnology, pharmaceutical sciences, and molecular biology, Dr. Prévot’s research focuses on the formulation and delivery of antisense oligonucleotides (ASOs), with a particular emphasis on enabling extra-hepatic targeting. He is involved in the design and evaluation of innovative delivery platforms aimed at enhancing the biodistribution, cellular uptake, and therapeutic potential of ASOs.
Seminars
As the brain and muscle remain key targets for LNP drug products, this workshop will explore the hurdles of the blood-brain barrier and broad muscle biodistribution. Gain insights and have proactive discussions into how to optimize LNP formulations to achieve efficient, specific and selective delivery to muscle and CNS targets. Topics include:
- Examining how to fine-tune LNP characteristics to enable efficient delivery across extensive muscle areas without compromising immunogenicity
- Uncovering ligand approaches for achieving selective LNP penetration across the blood–brain barrier
- Evaluating how dual-targeting strategies may navigate endothelial barriers to deliver payloads into muscle and brain
